K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 080 JPY -0.49% Market Closed
Market Cap: 154.5B JPY

Relative Value

The Relative Value of one Kaken Pharmaceutical Co Ltd stock under the Base Case scenario is hidden JPY. Compared to the current market price of 4 080 JPY, Kaken Pharmaceutical Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Kaken Pharmaceutical Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
31
vs Industry
53
Median 3Y
1.8
Median 5Y
1.9
Industry
2.7
Forward
1.8
vs History
0
vs Industry
40
Median 3Y
20.1
Median 5Y
15.2
Industry
21.6
Forward
48.3
vs History
vs Industry
45
Median 3Y
10
Median 5Y
10.7
Industry
16.9
vs History
vs Industry
32
Median 3Y
12.5
Median 5Y
13.7
Industry
22.9
vs History
33
vs Industry
58
Median 3Y
1
Median 5Y
1
Industry
2.3
vs History
6
vs Industry
70
Median 3Y
1
Median 5Y
1
Industry
3
Forward
1.2
vs History
7
vs Industry
74
Median 3Y
1.7
Median 5Y
1.8
Industry
5.6
vs History
0
vs Industry
49
Median 3Y
6
Median 5Y
4.5
Industry
13.4
Forward
13.9
vs History
0
vs Industry
47
Median 3Y
7.8
Median 5Y
5.1
Industry
16.7
vs History
vs Industry
50
Median 3Y
5.1
Median 5Y
5.4
Industry
16.1
vs History
vs Industry
38
Median 3Y
6.3
Median 5Y
7.1
Industry
18.9
vs History
26
vs Industry
60
Median 3Y
0.8
Median 5Y
0.8
Industry
2

Multiples Across Competitors

Competitors Multiples
Kaken Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Kaken Pharmaceutical Co Ltd
TSE:4521
154.5B JPY 1.9 237.3 23.1 61.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.4 37.2 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
511.7B USD 5.6 20.4 16.6 21.6
CH
Roche Holding AG
SIX:ROG
269.5B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 5 31 109.2 159.8
CH
Novartis AG
SIX:NOVN
216.4B CHF 4.8 18.9 11.9 15.4
US
Merck & Co Inc
NYSE:MRK
270.2B USD 4.2 14.2 10.1 11.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.5 16.6 11.6 13.4
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
142.4B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
JP
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Average P/E: 48.5
237.3
-54%
N/A
US
Eli Lilly and Co
NYSE:LLY
55.4
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.4
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
31
37%
0.8
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.6
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Average EV/EBITDA: 402.2
23.1
-42%
N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109.2
10%
10.9
CH
Novartis AG
SIX:NOVN
11.9
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
1%
11.6
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Average EV/EBIT: 1 718.1
61.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.6
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.8
23%
6.9
CH
Novartis AG
SIX:NOVN
15.4
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4